FindMyRecallSubscribe
Class II: temporary or reversible health riskCompleted

Hetero Labs Limited Unit V Camber Pharmaceuticals Recall

Camber Pharmaceuticals, Inc

Hetero Labs Limited Unit V

Risk level
Class II
Reported by FDA
Aug 29, 2018
Recall ID
D-1113-2018
Check your lot numberHow we source this data

Summary

Hetero Labs Limited Unit V recalled Camber Pharmaceuticals starting Aug 8, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1113-2018 on Aug 29, 2018. Reason: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. Status: Completed.

Why it was recalled

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Product description

Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 40 mg, 30 Tablets Rx Only Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854 By: Hetero Hetero Labs Limited Unit V, Polepally Jadcherla Mahaboob Nagar - 509-301, India. NDC 31722-745-30 UPC 331722745307

Lot numbers, UPCs & expiration codes

All Lots with expiration dates 7/2018 to 6/2020

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1113-2018
Classification
Class II
Status
Completed
Recall initiated
Aug 8, 2018
FDA report date
Aug 29, 2018
Quantity
316,380 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Hetero Labs Limited Unit V

Original FDA data

Every field from FDA enforcement report D-1113-2018, exactly as published.

Show all FDA fields
City
Jadcherla Mandal, Mahaboob Nagar
Status
Completed
Country
India
Event ID
80773
Address
Unit V (SEZ Unit I in APIIC SEZ)
Address (line 2)
Surv. No. 439-441, 458, Polepally Vill.
Code information
All Lots with expiration dates 7/2018 to 6/2020
Report date
Aug 29, 2018
Product type
Drugs
Recall number
D-1113-2018
Classification
Class II
Recalling firm
Hetero Labs Limited Unit V
Product quantity
316,380 bottles
Reason for recall
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 40 mg, 30 Tablets Rx Only Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854 By: Hetero Hetero Labs Limited Unit V, Polepally Jadcherla Mahaboob Nagar - 509-301, India. NDC 31722-745-30 UPC 331722745307
Distribution pattern
Nationwide
Recall initiation date
Aug 8, 2018
Initial firm notification
Letter
Center classification date
Aug 23, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1113-2018, published Aug 29, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls